This genomic study underlined that low-grade gliomas can present an IDH mutation with a 1p/19q codeletion or a TP53 mutation, and that the majority of these tumors with wild-type IDH showed genomic and clinical similarities to primary (wild-type IDH) GBM [31]. This evidence concerns the gene IDH2 and glioma.